Heron Therapeutics (HRTX) Equity Ratio (2010 - 2026)

Heron Therapeutics has reported Equity Ratio for 17 years, with the latest figure at 0.04 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 130.75% year-over-year to 0.04; the trailing twelve-month figure through Mar 2026 stood at 0.04 (up 130.75% YoY), and the FY2025 full-year result was 0.06, up 138.81% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.04, down from 0.06 in the prior quarter.
• The five-year high for Equity Ratio was 0.09 in Q1 2022, with the low at 0.2 in Q2 2023.
• Historically, Equity Ratio has averaged 0.07 across 5 years, with a median of 0.12 in 2025.
• Annual changes were most pronounced in 2023 — Equity Ratio slumped 382.32% — and 2025, when it soared 138.81%.
• Heron Therapeutics' Equity Ratio stood at 0.05 in 2022, then tumbled by 382.32% to 0.15 in 2023, then grew by 5.47% to 0.14 in 2024, then surged by 138.81% to 0.06 in 2025, then slumped by 33.75% to 0.04 in 2026.
• The last three Equity Ratio figures came in at 0.04 (Q1 2026), 0.06 (Q4 2025), and 0.06 (Q3 2025), per Business Quant data.